India’s 55th GST Council meeting, chaired by Union Finance Minister Nirmala Sitharaman, announced a complete exemption of Goods and Services Tax (GST) on gene therapy. This landmark decision reflects India’s commitment to advancing access to cutting-edge healthcare technologies and fostering innovation in the life sciences sector.

Gene therapy, a revolutionary medical technology that utilizes genetic engineering to treat or prevent a wide range of diseases, including rare genetic disorders and certain cancers, has been a game-changer in modern medicine. The elimination of GST on these therapies in India is expected to reduce treatment costs significantly, enhance accessibility for patients, and position India as a competitive destination for advanced healthcare solutions and clinical research.

This tax exemption is anticipated to:

• Lower the financial burden on patients seeking gene therapy in India.
• Strengthen India’s position as a global hub for biotechnology and advanced therapeutic research.
• Encourage investment in the development and deployment of gene therapies within India and worldwide.

Dr. Sanjay Gupta, a leading genetic medicine specialist, welcomed the move, stating, "India’s decision to exempt gene therapy from GST demonstrates visionary leadership in the healthcare domain. This will not only benefit domestic patients but also attract international attention to India’s growing capabilities in delivering world-class healthcare solutions."

The decision is set to ripple across the global healthcare landscape, offering multinational life sciences companies and healthcare providers opportunities to partner with Indian institutions for research, clinical trials, and patient outreach.

This tax exemption, effective immediately, also aligns with India's broader healthcare agenda, emphasizing affordability, accessibility, and excellence in advanced medical technologies.